1. Home
  2. PROV vs LCTX Comparison

PROV vs LCTX Comparison

Compare PROV & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROV
  • LCTX
  • Stock Information
  • Founded
  • PROV 1956
  • LCTX 1990
  • Country
  • PROV United States
  • LCTX United States
  • Employees
  • PROV N/A
  • LCTX N/A
  • Industry
  • PROV Savings Institutions
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PROV Finance
  • LCTX Health Care
  • Exchange
  • PROV Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • PROV 107.2M
  • LCTX 127.7M
  • IPO Year
  • PROV 1996
  • LCTX N/A
  • Fundamental
  • Price
  • PROV $16.04
  • LCTX $0.60
  • Analyst Decision
  • PROV Hold
  • LCTX Strong Buy
  • Analyst Count
  • PROV 1
  • LCTX 5
  • Target Price
  • PROV $16.00
  • LCTX $4.80
  • AVG Volume (30 Days)
  • PROV 7.4K
  • LCTX 2.4M
  • Earning Date
  • PROV 01-28-2025
  • LCTX 03-06-2025
  • Dividend Yield
  • PROV 3.49%
  • LCTX N/A
  • EPS Growth
  • PROV N/A
  • LCTX N/A
  • EPS
  • PROV 0.91
  • LCTX N/A
  • Revenue
  • PROV $38,443,000.00
  • LCTX $8,719,000.00
  • Revenue This Year
  • PROV N/A
  • LCTX N/A
  • Revenue Next Year
  • PROV $11.75
  • LCTX $41.15
  • P/E Ratio
  • PROV $17.64
  • LCTX N/A
  • Revenue Growth
  • PROV N/A
  • LCTX N/A
  • 52 Week Low
  • PROV $12.01
  • LCTX $0.48
  • 52 Week High
  • PROV $16.70
  • LCTX $1.61
  • Technical
  • Relative Strength Index (RSI)
  • PROV 56.92
  • LCTX 50.42
  • Support Level
  • PROV $15.00
  • LCTX $0.55
  • Resistance Level
  • PROV $16.29
  • LCTX $0.68
  • Average True Range (ATR)
  • PROV 0.50
  • LCTX 0.05
  • MACD
  • PROV 0.11
  • LCTX 0.00
  • Stochastic Oscillator
  • PROV 84.66
  • LCTX 40.47

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: